These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30798740)

  • 21. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
    Lazaraki G; Akriviadis E; Pilpilidis I; Parisi I; Tzilves D; Tarpangos A
    Am J Gastroenterol; 2011 Dec; 106(12):2204-6. PubMed ID: 22138950
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
    Amann A; Steiner N; Gunsilius E
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Poetker DM; Choong NW
    N Engl J Med; 2011 Feb; 364(7):688-9. PubMed ID: 21323562
    [No Abstract]   [Full Text] [Related]  

  • 28. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
    Karnezis TT; Davidson TM
    Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
    Kanellopoulou T; Alexopoulou A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
    Harrison L; Kundra A; Jervis P
    J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Bleeding.
    Gossage JR
    Mayo Clin Proc; 2018 Feb; 93(2):130-132. PubMed ID: 29395348
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
    Simonds J; Miller F; Mandel J; Davidson TM
    Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
    Alderman C; Corlett J; Cullis J
    Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
    [No Abstract]   [Full Text] [Related]  

  • 35. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avastin and diode laser: a combined modality in managing epistaxis in hereditary hemorrhagic telangiectasia.
    Marglani OA; Bawazeer NA; Abu Suliman OA
    Am J Otolaryngol; 2013; 34(5):603-5. PubMed ID: 23541684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
    Sautter NB; Smith TL
    Otolaryngol Clin North Am; 2016 Jun; 49(3):639-54. PubMed ID: 27267016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary hemorrhagic telangiectasia: a review of 76 cases.
    Shah RK; Dhingra JK; Shapshay SM
    Laryngoscope; 2002 May; 112(5):767-73. PubMed ID: 12150604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
    Fleagle JM; Bobba RK; Kardinal CG; Freter CE
    Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.